Aignostics

AI-powered tissue analysis, validated by pathologists

Founded 2018 Germany

Berlin, Germany 106 employees Series B Total: $53.80M AI, Health Care +1

General Information

Company Name Aignostics

Founded Year 2018

Location

Berlin, Germany

Employees 106

Industries AI, Health Care, Machine Learning

Funding Stage Series B

Business Model B2B, SaaS

Revenue Model Service Fee, Subscription, Usage Based

Hiring 2 roles posted in the month to 16 Oct 2026

Offices as of Sep 2026

Berlin, Germany

Social

BounceWatch is an independent company data service, not affiliated with Aignostics. To contact Aignostics, visit aignostics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Aignostics compare?

A PDF of Aignostics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Aignostics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

Product Launch Oct 16, 2026

Aignostics has launched HETA Clinical, AI Products to speed pathology workflows.

New Partnership Oct 16, 2026

Aignostics announced a collaboration with Techcyte to integrate AI-guided macrodissection into Techcyte Fusion® AP.

Award Received Oct 15, 2026

Aignostics has been selected as the winner of the "AI Startup Award" in the Best of AI Awards 2026, honoring startups integrating ethical and social values.

Actively Hiring Oct 13, 2026

Hiring for 2 positions in the last 30 days.

Event Participation Oct 02, 2026

Aignostics announced its participation as an exhibitor at ESMO in Madrid from October 23-26, located at Booth #1011.

Feature Release Sep 28, 2026

Aignostics announced two new updates to its Atlas H&E-TME application, expanding coverage to ten cancer types and splitting granulocytes into eosinophils and neutrophils.

Get alerts when Aignostics shows new signals

About Aignostics

Aignostics, established in 2018 as a spin-off from Charité Berlin, leverages AI and machine learning to drive advancements in precision diagnostics for pathology. Their innovative platform provides unparalleled insights across various therapeutic areas, making a significant impact on drug discovery, translational research, and clinical trials. With headquarters in Germany and operations in Berlin and New York, Aignostics represents a dynamic intersection of healthcare and technology.

The company recently secured a $34.00M Series B funding round on 01 October 2024, bolstered by industry heavyweights including IBB Ventures, Wellington Partners, HTGF, Mayo Clinic, CARMA FUND Management GmbH, Athos, and the Boehringer Ingelheim Venture Fund. This influx of capital underlines strong investor confidence in Aignostics' potential to spearhead the next generation of precision medicine solutions.

Business keywords: AI-powered precision diagnostics, multimodal clinical datasets, precision medicine, digital pathology, explainable AI, immuno-oncology, neurodegenerative disease, companion diagnostics, computational pathology, predictive analytics, deep learning, target identification, biomarkers, translational research, drug discovery

Services & Products

Target & Biomarker Discovery

Translational Research

Digital Diagnostics

Custom Image and Data Analysis

Target Customers

Life Sciences Companies Academic Institutions Healthcare Providers Research Organizations

Funding Rounds & Investors (6)

View All

Funding Stage	Amount	Investors	Lead Investors	Date
Series B	$34.00M	7	IBB Ventures, Wellington Partners +5	01 Oct 2024
Series A	€14.00M	4	IBB Ventures, Wellington Partners +2	01 Sep 2022
Seed	€5.00M	4	Future Capital, HTGF +2	01 Aug 2020
Seed	€600.00K	-		01 Apr 2019
Support Program	€200.00K	1	BIH Digital Health Accelerator	01 Jul 2018
Spinout	Undisclosed	3	Free University of Berlin, Humboldt University of Berlin +1	01 Jan 2018

Latest News

View All

NGS macrodissection workflow available from Techcyte and Aignostics

Cincinnati Enquirer Oct 16, 2026

Aignostics Launches HETA Clinical, AI Products to Speed Pathology Workflows, for Research Use Only

Konsulteer Oct 16, 2026

Berlin-based Aignostics secures €31.4 million Series B to enhance precision medicine with AI

Eu-startups Nov 01, 2024

19 AI healthtechs to watch, according to VCs

Sifted Apr 05, 2024

Aignostics Alternatives & Competitors

View All Alternatives

Aignostics vs

PredxBio United States

Reimagining Cancer Care with AI-Driven Spatial Biomarkers

Convertible Note

14 employees

AI, Biopharma

Compare Aignostics vs PredxBio

Aignostics vs

Ibex Medical Analytics United States

Pioneering AI-based cancer diagnostics in pathology

Series C

97 employees

AI, Analytics

Compare Aignostics vs Ibex Medical Analytics

Aignostics vs

radiomics.bio Belgium

Radiomics, Deep Learning & Federated Learning for AI powered drug development trajectory and persona...

24 employees

AI, Biotechnology

View all alternatives

FAQ About Aignostics

AI-powered tissue analysis, validated by pathologists

Aignostics was founded in 2018.

Aignostics is headquartered in Berlin, Germany.

Aignostics operates in AI, Health Care and Machine Learning. Its work centres on AI-powered precision diagnostics, multimodal clinical datasets, precision medicine and digital pathology. Its customers include Life Sciences Companies, Academic Institutions and Healthcare Providers.

Aignostics has a B2B and SaaS business model. Its revenue comes from Service Fee, Subscription and Usage Based.

Aignostics has approximately 106 employees.

Aignostics has completed 6 funding rounds, raising a total of $53.80M. The latest funding stage is Series B.

Aignostics offers: Target & Biomarker Discovery, Translational Research, Digital Diagnostics, Custom Image and Data Analysis.

Top alternatives and competitors to Aignostics include PredxBio, Ibex Medical Analytics, radiomics.bio, Multiomic Health, BlackThorn Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Aignostics and PredxBio are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Aignostics, https://bouncewatch.com/company/aignostics, updated 12 October 2026. When citing, please name BounceWatch and link this page.

Aignostics

General Information

Discover More

What changed at Aignostics recently?

About Aignostics

Services & Products

Target Customers

Funding Rounds & Investors (6)

Latest News

Aignostics Alternatives & Competitors

FAQ About Aignostics